A Phase 3 interventional study of ivacaftor and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 6 sites in 3 countries. Open to participants aged 3 Years to 5 Years. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 76th largest by enrollment, is one of 10 that started in 2016, is one of 45 in phase 3, and was the 40th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 3 Years to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 10 started in 2016.
This study's enrollment of 14 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 112th largest by enrollment of the 116 interventional ones that give a count, is one of 15 that started in 2016, is one of 62 in phase 3, and was the 52nd registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of ivacaftor treatment, as measured by lung clearance index (LCI), in subjects with cystic fibrosis (CF) who have a specified CF transmembrane conductance regulator (CFTR) gating mutation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ivacaftor in Treatment Period 1 →washout→placebo in Treatment Period 2
Drug: ivacaftor · Drug: Placebo
placebo in Treatment Period 1→washout→ivacaftor in Treatment Period 2
Drug: ivacaftor · Drug: Placebo
open label period
Drug: ivacaftor
Also known as: VX-770
Absolute Change From Baseline in Lung Clearance Index (LCI2.5) Through 8 Weeks of Treatment (Average of Week 4 and Week 8 LCI2.5)
LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
Time frame: Baseline Through Week 8 for each treatment period, Up to 24 Weeks
Absolute Change From Baseline in Immunoreactive Trypsinogen Levels at Week 8
Serum samples were collected for evaluation of change in immunoreactive trypsinogen levels at Week 8.
Time frame: Baseline and Week 8 of each treatment period, Up to 24 Weeks
Absolute Change From Baseline in Fecal Elastase-1 Levels at Week 8
Fecal elastase-1 was used clinically to diagnose pancreatic exocrine insufficiency in participants with cystic fibrosis.
Time frame: Baseline and Week 8 of each treatment period, Up to 24 Weeks
Absolute Change From Baseline in Weight at Week 8
Time frame: Baseline and Week 8 of each treatment period, Up to 24 Weeks
Absolute Change From Baseline in Body Mass Index (BMI) at Week 8
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).
Time frame: Baseline and Week 8 of each treatment period, Up to 24 Weeks
Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to Month 15
| Milestone | Part 1 Sequence 1: Ivacaftor First, Then Placebo | Part 1 Sequence 2: Placebo First, Then Ivacaftor | Part 2: Ivacaftor |
|---|---|---|---|
| Started | 8 | 6 | 0 |
| Completed | 8 | 6 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Part 1 Sequence 1: Ivacaftor First, Then Placebo | Part 1 Sequence 2: Placebo First, Then Ivacaftor | Part 2: Ivacaftor |
|---|---|---|---|
| Started | 8 | 6 | 0 |
| Completed | 7 | 5 | 0 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Availability of commercial drug | 1 | 1 | 0 |
| Milestone | Part 1 Sequence 1: Ivacaftor First, Then Placebo | Part 1 Sequence 2: Placebo First, Then Ivacaftor | Part 2: Ivacaftor |
|---|---|---|---|
| Started | 0 | 0 | 10 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 0 | 10 |
| Withdrew: Availability of commercial drug | 0 | 0 | 9 |
| Withdrew: Other | 0 | 0 | 1 |
LCI2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
| Lung clearance index | Placebo (Crossover Part) | Ivacaftor (Crossover Part) |
|---|---|---|
| Absolute Change From Baseline in Lung Clearance Index (LCI2.5) Through 8 Weeks of Treatment (Average of Week 4 and Week 8 LCI2.5) | -0.07 ± 0.93 | -0.53 ± 1.23 |
Serum samples were collected for evaluation of change in immunoreactive trypsinogen levels at Week 8.
| Nanogram per milliliter (ng/mL) | Placebo (Crossover Part) | Ivacaftor (Crossover Part) |
|---|---|---|
| Absolute Change From Baseline in Immunoreactive Trypsinogen Levels at Week 8 | -9.3 ± 18.4 | -15.5 ± 6.5 |
Fecal elastase-1 was used clinically to diagnose pancreatic exocrine insufficiency in participants with cystic fibrosis.
| microgram per gram (mcg/g) | Placebo (Crossover Part) | Ivacaftor (Crossover Part) |
|---|---|---|
| Absolute Change From Baseline in Fecal Elastase-1 Levels at Week 8 | -17.0 ± 55.4 | 23.1 ± 37.9 |
| Kilogram (kg) | Placebo (Crossover Part) | Ivacaftor (Crossover Part) |
|---|---|---|
| Absolute Change From Baseline in Weight at Week 8 | 0.9 ± 1.0 | 1.1 ± 0.9 |
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).
| Kilogram per meter square (kg/m^2) | Placebo (Crossover Part) | Ivacaftor (Crossover Part) |
|---|---|---|
| Absolute Change From Baseline in Body Mass Index (BMI) at Week 8 | 0.13 ± 0.79 | 0.32 ± 0.59 |
| Participants | Placebo (Crossover Part) | Ivacaftor (Crossover Part) | Ivacaftor (Open Label Part) |
|---|---|---|---|
| Participants with any AEs | 11 | 11 | 6 |
| Participants with SAEs | 0 | 0 | 0 |
Collected over Baseline up to Month 15. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Crossover Part) | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Ivacaftor (Crossover Part) | 0/13 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Ivacaftor (Open Label Part) | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Event | Placebo (Crossover Part) | Ivacaftor (Crossover Part) | Ivacaftor (Open Label Part) |
|---|---|---|---|
| CoughSkin and subcutaneous tissue disorders | 3/13 | 2/13 | 4/10 |
| VomitingGastrointestinal disorders | 1/13 | 3/13 | 3/10 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 3/13 | 3/13 | 3/10 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 3/13 | 3/13 | 0/10 |
| HeadacheNervous system disorders | 3/13 | 1/13 | 0/10 |
| Upper respiratory tract infectionInfections and infestations | 1/13 | 3/13 | 1/10 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/13 | 2/13 | 0/10 |
| Haemophilus test positiveInvestigations | 0/13 | 1/13 | 1/10 |
| Streptococcus test positiveInvestigations | 0/13 | 0/13 | 1/10 |
| WheezingRespiratory, thoracic and mediastinal disorders | 0/13 | 0/13 | 1/10 |
| Age, Continuous(years) | Part 1 Sequence 1: Ivacaftor First, Then Placebo | Part 1 Sequence 2: Placebo First, Then Ivacaftor | Total |
|---|---|---|---|
| Mean | 3.6 ± 0.7 | 4.2 ± 1.0 | 3.9 ± 0.9 |
| Sex: Female, Male(Participants) | Part 1 Sequence 1: Ivacaftor First, Then Placebo | Part 1 Sequence 2: Placebo First, Then Ivacaftor | Total |
|---|---|---|---|
| Female | 4 | 1 | 5 |
| Male | 4 | 5 | 9 |
| Race (NIH/OMB)(Participants) | Part 1 Sequence 1: Ivacaftor First, Then Placebo | Part 1 Sequence 2: Placebo First, Then Ivacaftor | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 8 | 6 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2016, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →